ethyl 1-acetyl-6-hydroxy-4-indolecarboxylate | 120587-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 1-acetyl-6-hydroxy-4-indolecarboxylate
• 英文别名: 1-Acetyl-6-hydroxy-1H-indole-4-carboxylic acid ethyl ester；ethyl 1-acetyl-6-hydroxyindole-4-carboxylate
• CAS: 120587-36-2
• 化学式: C₁₃H₁₃NO₄
• 分子量: 247.251
• InChiKey: VOJLOAJUEZQHRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 1-acetyl-6-hydroxy-4-indolecarboxylate 、 Methanesulfonic acid 2-phenyl-cyclopropylmethyl ester 、 potassium carbonate 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以Flash Chromatography afforded a white solid (96 mg)的产率得到6-(2-Phenyl-cyclopropylmethoxy)-1H-indole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY

  摘要：

  蛋白激酶，例如CHK-1，抑制以下式子中三环化合物（其中R2，R3和R4如规范所定义）的制剂（或其盐）的有效量的制药组合物，可用作单一剂量或与抗肿瘤剂或具有抗肿瘤作用的治疗性放射线组合使用，用于治疗癌症等疾病或病情。本发明涉及制备和使用这种化合物。

  公开号：

  US20070135415A1
• 作为产物：
  描述：

  1-(4H-呋喃并[3,2-b]吡咯-4-基)乙酮 、 丙炔酸乙酯 以 乙腈 为溶剂， 反应 32.0h， 以70%的产率得到ethyl 1-acetyl-6-hydroxy-4-indolecarboxylate
  参考文献：
  名称：

  Krutosikova, Alzbeta; Dandarova, Miloslava; Alfoeldi, Juraj, Collection of Czechoslovak Chemical Communications, 1988, vol. 53, # 8, p. 1770 - 1778

  摘要：

  DOI：

文献信息

• TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY
  申请人：Benedict Suzanne

  公开号：US20070135415A1

  公开（公告）日：2007-06-14

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R 2 , R 3 and R 4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.

  蛋白激酶，例如CHK-1，抑制以下式子中三环化合物（其中R2，R3和R4如规范所定义）的制剂（或其盐）的有效量的制药组合物，可用作单一剂量或与抗肿瘤剂或具有抗肿瘤作用的治疗性放射线组合使用，用于治疗癌症等疾病或病情。本发明涉及制备和使用这种化合物。
• US7462713B2
  申请人：——

  公开号：US7462713B2

  公开（公告）日：2008-12-09
• Krutosikova, Alzbeta; Dandarova, Miloslava; Alfoeldi, Juraj, Collection of Czechoslovak Chemical Communications, 1988, vol. 53, # 8, p. 1770 - 1778
  作者：Krutosikova, Alzbeta、Dandarova, Miloslava、Alfoeldi, Juraj、Kovac,Jaroslav

  DOI：——

  日期：——
• Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
  申请人：Benedict Suzanne

  公开号：US20060004052A1

  公开（公告）日：2006-01-05

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R 2 , R 3 and R 4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

  蛋白激酶（例如CHK-1）抑制下列式子中三环化合物（其中R2，R3和R4如规范中定义）的药物组合物（或其盐）在单独使用或与具有抗肿瘤作用的抗肿瘤剂或治疗性放射线组合使用时，可用于治疗癌症等疾病或病况。